

Komzifti

Nepal · access guide

Komzifti in Nepal

Komzifti - overview

Komzifti (ziftomenib) is manufactured by Kura Oncology and indicated for R/R NPM1-mutant acute myeloid leukemia (AML). It is an oral small molecule approved by the US FDA in 2025 and may be accessible to patients in Nepal through a Named Patient Program or personal-import pathway.

Access in Nepal

Nepal's DDA has a personal-use pathway; volumes are small but process exists.

How Reserve Meds coordinates access in Nepal

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Nepal-specific eligibility.
3. Treating physician in Nepal issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Komzifti from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Nepal.

Typical timeline for Nepal

End-to-end, most requests are completed in 2-6 weeks. Nepal's tier 3 regulatory maturity typically supports longer processing times.

What patients and physicians in Nepal ask

- Is the pathway legal in Nepal? **Yes** - it operates under Nepal's established NPP or personal-import framework.
- Does my insurance cover it? **Typically no** for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? **A licensed physician in Nepal** able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Komzifti in Nepal

Start your case Or message us on WhatsApp

About Komzifti

Oncology (Leukemia)

Manufacturer: Kura Oncology

Modality:

Full drug page ->

About Nepal

South Asia

Tier 3

Full country page ->

See also

Access pathways

Articles & guides

Clinical resource (HCP)

YELLOW AI Regulatory Review Agent, preliminary signal Biologic drug requires DDA import confirmation for the specific patient indication. Cold-chain shipping validated. Typically 2-4 week approval. Rule:

biologic_moh_confirmation • Reviewed 2026-04-22

Start your case Or message us on WhatsApp

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

Reserve Meds

reserved for you.

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com